Literature DB >> 25440223

Clinical use of microRNAs as potential non-invasive biomarkers for detecting non-small cell lung cancer: a meta-analysis.

Huoqiang Wang1, Songnian Wu, Long Zhao, Juan Zhao, Jinjun Liu, Zhihao Wang.   

Abstract

Emerging studies have revealed that microRNA (miRNA) in body fluid may serve as a potential biomarker to detect non-small cell lung cancer (NSCLC). However, the diagnostic accuracy of miRNA for NSCLC detection is still under debate because there is inconsistency in previous studies. Hence, we conducted this meta-analysis to comprehensively evaluate the diagnostic performance of miRNA. A systematic literature search was performed to retrieve relevant articles in PubMed and other databases, and STATA 12.0 (StataCorp, College Station, TX, USA) was used to calculate the pooled parameters. A total of 28 articles involving 2121 NSCLC patients and 1582 healthy controls were included in this meta-analysis. The overall pooled sensitivity and specificity of miRNA were 0.75 and 0.79, respectively. The pooled positive likelihood ratio was 3.6, negative likelihood ratio was 0.32 and diagnostic odds ratio was 12. The area under the curve (AUC) was 0.84. Subgroup and meta-regression analyses established that miRNA assays were more accurate in Caucasian populations (AUC of 0.86, sensitivity of 0.79 and specificity of 0.82, respectively) than in Asian populations (AUC, sensitivity and specificity of 0.83, 0.72 and 0.80, respectively). In addition, the multiple miRNA assays (AUC of 0.89, sensitivity of 0.83 and specificity of 0.82, respectively) showed a higher accuracy than single miRNA assays (AUC, sensitivity and specificity of 0.81, 0.77 and 0.71, respectively) in NSCLC detection. Subgroup analyses based on specimen types suggested that blood-based miRNA (AUC of 0.86, sensitivity of 0.78 and specificity of 0.80, respectively) may have a higher diagnostic accuracy as biomarkers than sputum-based miRNA (AUC of 0.81, sensitivity of 0.69 and specificity of 0.80, respectively). In conclusion, miRNA may serve as a potential biomarker in NSCLS detection, especially the multiple miRNA from blood, with a relatively high diagnostic accuracy.
© 2014 Asian Pacific Society of Respirology.

Entities:  

Keywords:  diagnostic; meta-analysis; microRNA; non-small cell lung cancer

Mesh:

Substances:

Year:  2014        PMID: 25440223     DOI: 10.1111/resp.12444

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  22 in total

Review 1.  miRNAs as Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer: Current Perspectives.

Authors:  Mateusz Florczuk; Adam Szpechcinski; Joanna Chorostowska-Wynimko
Journal:  Target Oncol       Date:  2017-04       Impact factor: 4.493

Review 2.  Clinical applications of liquid biopsies for early lung cancer detection.

Authors:  Hao Zheng; Xin Wu; Jie Yin; Shuang Wang; Zhi Li; Changxuan You
Journal:  Am J Cancer Res       Date:  2019-12-01       Impact factor: 6.166

Review 3.  Liquid biopsy for lung cancer early detection.

Authors:  Mariacarmela Santarpia; Alessia Liguori; Alessandro D'Aveni; Niki Karachaliou; Maria Gonzalez-Cao; Maria Grazia Daffinà; Chiara Lazzari; Giuseppe Altavilla; Rafael Rosell
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

4.  Overexpression of miR-1260b in Non-small Cell Lung Cancer is Associated with Lymph Node Metastasis.

Authors:  Limin Xu; Liqin Li; Jing Li; Hongwei Li; Qibin Shen; Jinliang Ping; Zhihong Ma; Jing Zhong; Licheng Dai
Journal:  Aging Dis       Date:  2015-11-17       Impact factor: 6.745

Review 5.  miRNAs as biomarkers and for the early detection of non-small cell lung cancer (NSCLC).

Authors:  Yichao Han; Hecheng Li
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

6.  Associations of mRNA:microRNA for the Shared Downstream Molecules of EGFR and Alternative Tyrosine Kinase Receptors in Non-small Cell Lung Cancer.

Authors:  Fengfeng Wang; Fei Meng; Lili Wang; S C Cesar Wong; William C S Cho; Lawrence W C Chan
Journal:  Front Genet       Date:  2016-10-13       Impact factor: 4.599

7.  Diagnostic value of strand-specific miRNA-101-3p and miRNA-101-5p for hepatocellular carcinoma and a bioinformatic analysis of their possible mechanism of action.

Authors:  Xia Yang; Yu-Yan Pang; Rong-Quan He; Peng Lin; Jie-Mei Cen; Hong Yang; Jie Ma; Gang Chen
Journal:  FEBS Open Bio       Date:  2017-12-20       Impact factor: 2.693

8.  Polymorphisms of pri-miR-219-1 are associated with the susceptibility and prognosis of non-small cell lung cancer in a Northeast Chinese population.

Authors:  Chang Zheng; Xuelian Li; Lingzi Xia; Xue Fang; Xiaowei Quan; Zhihua Yin; Yuxia Zhao; Baosen Zhou
Journal:  Oncotarget       Date:  2017-04-11

9.  MiR-138 inhibits cell proliferation and reverses epithelial-mesenchymal transition in non-small cell lung cancer cells by targeting GIT1 and SEMA4C.

Authors:  Jiefang Li; Qinrong Wang; Ruiling Wen; Jieman Liang; Xiaoling Zhong; Wei Yang; Dongxiang Su; Jun Tang
Journal:  J Cell Mol Med       Date:  2015-08-18       Impact factor: 5.310

Review 10.  Systematic review and critique of circulating miRNAs as biomarkers of stage I-II non-small cell lung cancer.

Authors:  Francesca Moretti; Paola D'Antona; Emanuele Finardi; Marco Barbetta; Lorenzo Dominioni; Albino Poli; Elisabetta Gini; Douglas M Noonan; Andrea Imperatori; Nicola Rotolo; Maria Cattoni; Paola Campomenosi
Journal:  Oncotarget       Date:  2017-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.